Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2010 - 2023)

Jazz Pharmaceuticals' Current Deferred Revenue history runs 14 years deep, the most recent figure standing at $4000.0 for Q3 2023.

• In Q3 2023, Current Deferred Revenue fell 99.54% year-over-year to $4000.0; the TTM figure through Sep 2023 stood at $4000.0 (down 99.54% YoY), while the FY2022 annual figure was $463000.0, down 77.88% from the prior year.
• Current Deferred Revenue was $4000.0 for Q3 2023 at Jazz Pharmaceuticals, roughly flat from $4000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.9 million in Q2 2019 to a low of $4000.0 in Q1 2023.
• Historically, Current Deferred Revenue has averaged $3.6 million across 5 years, with a median of $3.6 million in 2020.
• The sharpest annual moves came in 2019 and 2023: Current Deferred Revenue jumped 84.96% in 2019, then tumbled 99.76% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $4.7 million in 2019, then rose by 2.99% to $4.9 million in 2020, then tumbled by 56.94% to $2.1 million in 2021, then tumbled by 77.88% to $463000.0 in 2022, then tumbled by 99.14% to $4000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $4000.0 (Q3 2023), $4000.0 (Q2 2023), and $4000.0 (Q1 2023), per Business Quant data.